We aim to be the world-leading immuno-oncolytic virus company, delivering medicines of value to patients with cancer.
Our work is product and platform based with a focus on discovering and developing innovative oncolytic viruses for the treatment of solid tumors. We will optimize our pipeline by focusing on advancing our internal clinical candidates and establishing strategic partnerships with leading immuno-oncology companies and academic groups to further expand our portfolio of cancer therapeutics.
We choose to fight cancer
alongside all of those patients who did not choose to be in that fight.
We choose to make a difference
because innovation and science can push the boundaries of what is possible.
We choose to work with honesty and integrity
because we recognise the important responsibilities that we have.
We choose to respect each other and our partners
because by working together we can achieve so much more than by working alone.